FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Salt Policy to Avoid Medication Errors

[ Price : $8.95]

CDER pharmacists Catherine Chew and Lindsay Davison say a new USP naming policy for salt drug substances should help reduce medica...

FDA Urged to Speed Biosimilar Developments

[ Price : $8.95]

FDA deputy commissioner Sally Howard says that while the agency has been slow in issuing guidance for biosimilars, it is reviewing...

CorMedix Seeks QIDP Designation for Neutrolin

[ Price : $8.95]

CorMedix, Inc. files an application with FDA seeking Qualified Infectious Disease designation for its Neutrolin Catheter Lock solu...

Guidance on Pregnancy/Lactation Labeling for Drugs/Biologics

[ Price : $8.95]

Federal Register Notice: FDA releases a draft guidance: Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Presc...

FDA Changes Pregnancy Labeling of Drug/Biologics

[ Price : $8.95]

Federal Register Final rule: FDA amends its regulations on the content and format of Pregnancy, Labor and delivery, and Nursing mo...

FDA Clears ArtVentive Medical Occlusion System

[ Price : $8.95]

FDA clears an ArtVentive Medical Group 510(k) for its Endoluminal Occlusion System that is intended for use in the peripheral vasc...

Incytes Jakafi sNDA Approved for Bone Marrow Disease

[ Price : $8.95]

FDA approves an Incyte Corp. supplemental NDA for Jakafi (ruxolitinib) for treating patients with polycythemia vera, a chronic typ...

FDA Clears Fiagon AG Navigation Extended Instrument Set

[ Price : $8.95]

FDA clears a Fiagon AG 510(k) for its ear, nose and throat Extended Instrument Set.

Ebola Priority Review Voucher Bill Goes to House

[ Price : $8.95]

The Senate approves unanimously legislation adding Ebola as a qualifying disease for the FDA priority review voucher program.

FDAers Push Random Ebola Therapy Trials

[ Price : $8.95]

Three FDAers make the case for randomized, controlled trials rather than an historical control in evaluating potential Ebola thera...